Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety

Mitchell, Jon-Benay; Chetty, Sarentha; Kathrada, Fatima

doi:10.1186/s12905-022-02122-0

BMC Women's Health

Table 2 Characteristics of the studies on the use of progestins for the symptomatic relief of endometriosis pain

From: Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety

Source	Study design	Year of enrolment	Description of main symptoms	Number of patients enrolled	Study drug	Comparator	Number of patients treated with the study drug	Number of patients treated with comparator	Treatment period	Study outcomes
Petraglia et al. [34]	Randomised open-label, placebo-controlled trial	2004–2007	Pelvic Pain	168	Dienogest 2 mg/d	Placebo	87	81	52 weeks	Pain improvement (VAS) Adverse effects
Morotti et al. [35]	Open-label prospective trial	2014	Pelvic Pain	25	Norethisterone acetate 2.5-5 mg/d	Dienogest 2 mg/d	25	25	6 months	Adverse effects
Vercellini et al. [36]	Retrospective and prospective study	2012–2014	Pelvic Pain	180	Norethisterone acetate 2.5	Dienogest 2 mg/d	90	90	6 months	Pain improvement (NRS)
Morotti et al. [37]	Retrospective study	2004–2016	Pelvic Pain	103	Norethisterone acetate 2.5-5 mg/d	N/A	103	N/A	60 months	Pain improvement (VAS) Adverse effects
Maiorana et al. [38]	Observational, single-centre cohort study	2013–2014	Pelvic Pain	132	Dienogest 2 mg/d	N/A	132	N/A	12 months	Pain improvement (VAS) Adverse effects
Römer [39]	Retrospective study	2016	Pelvic Pain	37	Dienogest 2 mg/d	N/A	37	N/A	60 months	Adverse effects
Vercellini et al. [40]	Prospective study	2014	Pelvic Pain	153	Norethisterone 2.5 mg/d	N/A	153	N/A	12 months	Pain improvement (NRS) Adverse effects
Sansone et al. [41]	Multicenter prospective observational study	2016	Pelvic Pain	25	Etonogestrel implant	N/A	25	N/A	12 months	Pain improvement (VAS) Adverse effects
Lang et al. [42]	Randomised double-blind, placebo-controlled trial	2013	Pelvic Pain	255	Dienogest 2 mg/d	Placebo	126	129	24 weeks	Pain improvement (VAS) Adverse effects.
Yu et al. [43]	Open-label extension study	2018	Pelvic Pain	220	Dienogest 2 mg/d	Placebo	111	109	28 weeks	Pain improvement (VAS) Adverse effects
Carvalho et al. [44]	Open-label parallel-group, non-inferiority, randomised clinical trial	2016	Pelvic Pain	103	Etonogestrel implant	52 mg Levonorgestrel-releasing intrauterine system	52	51	6 months	Pain improvement (VAS)
Del Forno et al. [45]	Retrospective study	2015	Pelvic Pain	135	Dienogest 2 mg/d	Norethisterone acetate 2.5 mg/d	69	66	12 months	Adverse effects
Ferrero et al. [46]	Retrospective study	2019	Pelvic Pain	44	Etonogestrel implant	N/A	44	N/A	24 months	Pain improvement (VAS) Adverse effects
Cho et al. [47]	Prospective cohort study	2011–2017	Pelvic Pain	3356	Dienogest 2 mg/d	N/A	3356	N/A	12 months	Pain improvement (VAS) Adverse effects
Barra et al. [48]	Retrospective study	2019	Pelvic Pain	83	Dienogest 2 mg/d	N/A	83	N/A	36 months	Pain improvement (VAS) Adverse effects
Margatho et al. [32]	Randomised control trial	2016–2019	Pelvic Pain and dysmenorrhoea	103	Etonogestrel implant	52 mg Levonorgestrel-releasing intrauterine system	52	51	24 months	Pain improvement (VAS)
Nirgianakis et al. [49]	Retrospective cohort study	2017–2018	Pelvic Pain	130	Dienogest 2 mg/d	N/A	130	N/A	36 weeks	Pain improvement (VAS) Adverse effects
Kitawaki et al. [50]	Post-marketing observational study	2016–2017	Pelvic Pain	59	Dydrogesterone 10 mg twice daily	N/A	59	N/A	six 21-day cycles	Pain improvement (VAS) Adverse effects

VAS Visual analogue scale, NRS Numerical rating scale

Back to article page

ISSN: 1472-6874

Contact us

Submission enquiries: bmcwomenshealth@biomedcentral.com
General enquiries: ORSupport@springernature.com